Clinical Trials

Metastatic Castration-resistant Prostate Cancer

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03431350 2026-04-13

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 2 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Prostatic Neoplasms

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1 Completed

247 enrolled 53 charts

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 2 FDA

LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

175 enrolled 23 charts

Tumor-Agnostic

Neoplasms

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

706 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03072238 2025-06-06

IPATential150

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT01974440 2025-05-25

SELENE

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03384654 2025-05-25

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

LymphoidOther hematologic neoplasm

47 enrolled 22 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

265 enrolled 21 charts 4 FDA

Plasma cell

Multiple Myeloma

NCT03706365 2025-04-20

CYCLONE 2

Phase 2/3 Active not recruiting

393 enrolled 23 charts

Prostatic Neoplasms

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

19 enrolled 11 charts

Adenocarcinoma, Prostatic Neoplasms

NCT02043678 2025-02-19

ERA 223

806 enrolled 32 charts

Prostatic Neoplasms

NCT00887198 2025-02-04

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

1,088 enrolled 14 charts

Prostatic Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

117 enrolled 26 charts

Lymphoma, B-Cell

NCT02626455 2024-12-11

CHRONOS-4

Phase 3 Terminated

551 enrolled 32 charts

Lymphoma, Non-Hodgkin

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

60 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT02406092 2024-11-21

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

139 enrolled 14 charts

Lymphoma, Non-Hodgkin

NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

72 enrolled 21 charts

Metastatic Castration-Resistant Prostate Cancer

NCT04745832 2024-11-04

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Phase 3 Terminated

82 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02348216 2024-06-04

ZUMA-1

307 enrolled 41 charts

Lymphoma, Large B-Cell, Diffuse

NCT04887506 2024-01-16

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

107 enrolled 20 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

158 enrolled 32 charts

Prostatic Neoplasms

NCT02617485 2023-10-25

MADILYM

143 enrolled 25 charts

Lymphoma, Large B-Cell, Diffuse

NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

50 enrolled 25 charts

Lymphoma, Large B-Cell, Diffuse

NCT01995513 2023-09-18

PLATO

Phase 4 Completed

509 enrolled 18 charts

Prostatic Neoplasms

NCT01485861 2023-09-14

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

298 enrolled 58 charts

Prostatic Neoplasms

NCT02285062 2023-06-22

ROBUST

570 enrolled 27 charts

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

46 enrolled 20 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT01992653 2023-03-14

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

85 enrolled 34 charts

Lymphoma, Non-Hodgkin

NCT01332968 2022-08-11

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

1,401 enrolled 40 charts

Lymphoma, Non-Hodgkin

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1 Terminated

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT02485691 2022-05-27

CARD

Phase 4 Completed

255 enrolled 21 charts